Raymond James analyst Jayson Bedford downgraded Edwards Lifesciences to Market Perform from Outperform without a price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EW:
- Early notable gainers among liquid option names on February 1st
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c
- Edwards Lifesciences backs FY23 adjusted EPS $2.45-$2.60, consensus $2.50